Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid Use.
Surya P Bhatt, Fernando J Martinez, Imran Satia, Antonio Anzueto, Jean Bourbeau, Alberto Papi, Stephanie Korn, Gaëtan Deslée, Changming Xia, Jigna Heble, Mena Soliman, Mona Bafadhel
Am J Respir Crit Care Med aamag227
摘要
摘要
RATIONALE: In chronic obstructive pulmonary disease, exacerbations drive morbidity, healthcare resource utilization, and mortality. Hospitalization and emergency department visits reflect acute clinical instability. Systemic corticosteroids are usually prescribed for exacerbations, but cumulative exposure is a concern. OBJECTIVES: To evaluate the effect of dupilumab on emergency department visits/hospital admissions and systemic corticosteroid use in patients experiencing exacerbations. METHODS: BOREAS and NOTUS, two phase 3, randomized, double-blind, placebo-controlled trials, enrolled patients (40-85 years) with chronic obstructive pulmonary disease, moderate-to-severe airflow limitation, and type 2 inflammation (screening blood eosinophil count ≥ 300 cells/µL). Patients received dupilumab 300 mg (N = 938) or placebo (N = 936) for 52 weeks. Systemic corticosteroid use and annualized rate and time to first emergency department visit/hospital admission were assessed. MEASUREMENTS AND MAIN RESULTS: Dupilumab versus placebo reduced emergency department visits/hospital admissions of any duration by 38% (relative risk: 0.62 [95% confidence interval: 0.43-0.90]; P = .0121), delayed time to first event, and reduced risk of a first event by 45% (hazard ratio: 0.55 [95% confidence interval: 0.38-0.78]; P = .0010). Compared with placebo, systemic corticosteroid use was reduced in patients treated with dupilumab who experienced severe exacerbations by 42% (relative risk: 0.58 [95% confidence interval: 0.38-0.89]; P = .0126) and moderate exacerbations by 28% (relative risk: 0.72 [95% confidence interval: 0.60-0.87]; P = .0005). CONCLUSIONS: Dupilumab reduced emergency department visits/hospital admissions of any duration. Patients who experienced moderate and/or severe exacerbations required fewer systemic corticosteroids with dupilumab compared with placebo.
KM 提取结果
0 个 Figure · 0 个 KM 面板